Reply to letter: Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia

Affiliations

¹ School of Public Health and Community Medicine, UNSW Australia, Sydney, NSW, Australia. Electronic address: a.newall@unsw.edu.au.
² School of Public Health and Community Medicine, UNSW Australia, Sydney, NSW, Australia.
³ National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases (NCIRS), Kids Research Institute, Children's Hospital at Westmead, NSW, Australia.
⁴ School of Public Health and Community Medicine, UNSW Australia, Sydney, NSW, Australia; Centre for Health Economics Research and Modelling Infectious Diseases (CHERM ID), Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp, Belgium.

Comment

A T Newall et al. Vaccine. 2019.

. 2019 Dec 10;37(52):7534.

doi: 10.1016/j.vaccine.2019.09.108. Epub 2019 Nov 14.

¹ School of Public Health and Community Medicine, UNSW Australia, Sydney, NSW, Australia. Electronic address: a.newall@unsw.edu.au.
² School of Public Health and Community Medicine, UNSW Australia, Sydney, NSW, Australia.
³ National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases (NCIRS), Kids Research Institute, Children's Hospital at Westmead, NSW, Australia.
⁴ School of Public Health and Community Medicine, UNSW Australia, Sydney, NSW, Australia; Centre for Health Economics Research and Modelling Infectious Diseases (CHERM ID), Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp, Belgium.

No abstract available

Keywords: Adult vaccination; Economic evaluation; Elderly; PPV23; Pneumococcal; Pneumonia.

Comment on

Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia.
Van Buynder P, Cripps AW. Van Buynder P, et al. Vaccine. 2019 May 27;37(24):3141. doi: 10.1016/j.vaccine.2019.03.079. Vaccine. 2019. PMID: 31084782 No abstract available.